Recently, western countries have recorded a decrease in the death rate imputed to AIDS. This success has been largely attributed to the presence on the market of chemotherapies that inhibit the infectivity of the predominant causative agent, the HIV-1 virus, by targeting essential viral enzymes. One of these is the protease (HIV-1 PR) whose activity is a prerequisite for viral replication. Two main sites have been identified as potential targets for the inhibition of HIV-1 PR, the active site and the interface, the latter being largely responsible for the stabilization of the enzyme dimeric structure. The compounds that have reached clinical application so far target the active site of HIV-1 PR. These molecules act as transition state analogues and result from modifications of the peptidic scaffold into peptidomimetics. In order to improve their bioavailability, systematic biological screening and de novo design have been used to suggest new non-peptide inhibitors combining both antiviral potency and favorable pharmacokinetic properties. In parallel, compounds targeting other potential sites of inhibition have been tested. Peptides and peptidomimetics based on the terminal sequence of the enzyme, a site which is proposed to be less susceptible to mutations, have been shown to lead to HIV-1 PR inactivation. Cupric ion was described to bind a sequence on the protease surface, which includes cysteine and histidine residues, leading to the inhibition of the enzyme. In the future, these non-active site inhibitors could provide an alternative in anti-HIV drug combination strategies.
Introduction
process catalyzed by a viral integrase (HIV-1 IN). Once cell activation occurs, the proviral DNA is transcribed into genomic RNA and mRNA. Translation of viral mRNA gives rise to three precursor polyproteins gag (Pr55gag), gag-pol (Pr160gag-pol) and env (gp160), containing respectively the structural proteins (p17, p24, p7 and p6), the viral enzymes (RT, IN and PR) and the envelope glycoproteins (gp41, gp120). These polyproteins assemble at the membrane and form new viral particles that become infectious upon cleavage of the precursor polyproteins gag and gag-pol by a viral protease (HIV-1 PR). The resultant understanding of HIV-1 life cycle at the molecular level has suggested many targets for intervention, and in particular the three viral enzymes HIV-1 RT, IN and PR, essential for virus replication [5] . As early as 1985, AZT was approved as the first HIV-1 antiviral drug targeting the viral RT. AZT exerts its pharmacological effect by being incorporated into the growing DNA chain and preventing further growth. However, with AZT, as with many nucleoside analogues, toxicity is still a problem [6] . Nonnucleosides (NN) inhibitors, targeting an allosteric site of RT have been successfully designed and synthesized. First generation NNRTIs are rapidly inactivated through mutations of the enzyme ( [7, 8] and references therein) however, a potent NNRTI that is The pandemic spread of the acquired immunodeficiency syndrome (AIDS), with more than 30 million people infected since the beginning of the infection, has promoted an unprecedented scientific and clinical effort to understand and combat this lethal disease. First reported in the beginning of the 80's, AIDS is associated with a depletion of T lymphocytes causing various opportunistic infections among which is the rare combination among young individuals of Pneumocystis carinii and Kaposi's sarcoma. Following the isolation of AIDS causative agent, the human immunodeficiency virus (HIV-1) [1, 2] , intense research has led to an understanding of the processes involved in the replication machinery of HIV-1. Its viral genome is typical of retroviruses and consists of duplicate copies of single stranded RNA [3, 4] . Once the cell becomes infected with the virus, the genetic information flows from RNA to DNA by means of a viral reverse transcriptase (HIV-1 RT). The viral DNA genome becomes permanently integrated in the host cell by a much less liable to select for resistant virus has been recently introduced [9] [10] [11] [12] .
have been identified as potential targets for the inhibition of HIV-1 PR, the active site and the interface, the latter being largely responsible for the stabilization of the enzyme dimeric structure. Recently, light has been cast on a new potential site of inhibition that involves interaction with metal-binding residues on the surface of the protease.
As the proteolytic activity of the PR is absolutely required for the production of mature, infectious viral particles, this enzyme was soon recognized as an attractive target for therapeutic intervention [13] . Since 1995, four HIV-1 protease (PR) inhibitors have been approved by US Federal Drug Administration (FDA). Currently licensed protease inhibitors include Invirase ® (saquinavir mesylate, Hoffmann-LaRoche), Norvir ® (ritonavir, Abbott Laboratories), Crixivan ® (indinavir sulfate, Merck) and more recently Viracept ® (nelfinavir mesylate, Agouron Pharmaceuticals). A number of other compounds such as Amprenavir (VX-478, Glaxo Wellcome), Tripranavir (PNU-140690, PharmaciaUpjohn) and DMP-450 (Triangle) are in clinical development. The reduction in mortality in AIDS patients after treatment with combination therapy including RT and PR inhibitors has been particularly impressive [14] . Although they are no cure, they can significantly inhibit viral replication. The long-term clinical efficacy of these compounds is still under investigation, but the emergence of resistant viruses appears to be a potential limitation for all of them. The peptide-like nature and size of most HIV-1 PR inhibitors limit their oral bioavailability and half-life in man, making high blood levels difficult to achieve and sustain. However, this first success in the history of AIDS chemotherapy encourages research aimed at proposing new generations of anti-proteases, able to suppress viral replication and to delay the appearance of resistance. This review is not intended to provide a comprehensive list of all currently available HIV-1 antiviral compounds but to describe the various methods that were used to discover anti-HIV-1 PR agents and to indicate promising new strategies.
Active-site Inhibitors
Active site inhibitors have been extensively studied. They present a large structural variety that points to the chemical tolerance of the active site. The structural determination of numerous HIV-1 PR/inhibitor crystallographic complexes has revealed a similar mode of interaction of most inhibitors with the active site of the enzyme, as depicted in Fig. (1 ) . A common feature observed is the presence of a tetracoordinated water molecule linking the bound inhibitor to the flexible β-strands or "flaps" of the HIV-1 PR dimer. This water molecule accepts two hydrogen bonds from backbone amide hydrogen atoms of HIV-1 PR residues Ile 50 and Ile 50' and donates two hydrogen bonds to carbonyl oxygen atoms of the inhibitor, thus inducing the fit of the flaps over the inhibitor.
Opposite the flaps region, two catalytic aspartates Asp 25 and Asp 25' interact through hydrogen bonds with one (in some cases two) hydroxyl group(s) belonging to the non-cleavable transition-state isostere of the inhibitor (In Schechter & Berger's nomenclature, residues to the left of the isostere are referred to as the P 1 , P 2 , P 3 , etc. position, and those to the right are given the designation P' 1 , P' 2 , P' 3 , etc. Similarly, HIV-1 PR binding pockets are designated S 1 , S 2 , S 3 and S' 1 , S' 2 , S' 3 ). This hydroxyl group shifts and replaces the catalytic water molecule that initiates the hydrolysis process. On each side of these interactions that were soon recognized as essential, hydrogen bonds are formed between the inhibitor and residues Gly 27 (27'), Ala 28 (28'), Asp 29 (29'), Asp 30 (30') and Gly 48 (48' ). The inhibitor is further maintained into the enzymatic cleft by a multitude of van der Waals contacts. It is interesting to note that fullerene derivatives were shown to be active against HIV-1 PR (K i =5 µM), elegantly demonstrating the highly hydrophobic character of the active site [19] [20] [21] [22] . Several methodologies have been applied for lead generation using 1) the structure of enzyme substrates as a starting point for drug discovery (substrate-based approach) 2) biological screening methodologies developed to test hundreds/thousands of compounds (screening approach) 3) X-ray crystallography data of HIV-1 PR-inhibitor complexes (biostructural approach or "rational drug design").
Design of HIV-1 Protease Inhibitors
Since the first crystallographic structure of HIV-1 PR was released [15] [16] [17] , more than 80 crystallographic structures of native HIV-1 PR or in complex with various inhibitors are now presently available in the PDB. This mine of structural information makes HIV-1 PR one of the most well known enzyme to date. HIV-1 PR belongs to the aspartic protease group of enzymes, like renin and endothiopepsin. HIV-1 PR is unique with respect to other retroviral proteases as it is active as an obligatory homodimer stabilized by non covalent interactions [15, 16] . Each subunit contributes one of the two conserved triads (Asp-Thr-Gly) containing the catalytically active aspartate residues [18] . These aspartates are located at the center of a hydrophobic cleft of sufficient length to accept six amino acids of the substrate in an extended conformation. Two main sites Fig. (1) . Model of the interaction between HIV-1 PR active site and the substrate (or peptidic/peptidomimetic inhibitors). HIV-1 PR residues have been represented in green. In peptidic/peptidomimetic inhibitors the hydrolysis unit (in blue) in the peptide chain has been replaced with non-cleavable isosteric fragments. Two essential interactions (in red) involve flaps residues Ile 50/50' and catalytic residues Asp 25/25' of the protease.
Substrate-based approach
molecule is delivered by two aspartic acids to the substrate cleavage site, creating a tetrahedral transition-state intermediate, which rapidly breaks apart to give a C-terminal acid and a N-terminal amine.
The substrate clearly represents a molecule that interacts with the enzyme, and as such forms a lead structure. The similarities between HIV protease and renin allowed medicinal chemists to make rapid use of the information gained from renin inhibitor projects, in which transition state mimetics were used to achieve isolated enzyme activity. Similarly, when HIV-1 protease cleaves a protein substrate as shown in Fig. (2 ) , a water It was recognized at an early stage that mimics of the tetrahedral intermediate of the reaction catalyzed by the enzyme might be excellent inhibitors. The first inhibitors that were designed were based on the structure of the proteolysis products of polyproteins Pr55 gag and Pr160 gagpol , substrates of HIV-1 PR, and in particular on the hydrolysis site Phe*Pro, specific of retroviral proteases (see Fig. (3 ) ). Fig. (3) . Amino acid residues of the PR/RT cleavage site, highly specific of retroviral proteases and their associated position P 1 , P 2 , P 3 / P' 1 , P' 2 , P' 3 in the enzyme active site.
bioavailability and are rapidly metabolized in vivo. Systematic modification of the substrate-based peptides using rational design techniques (see below) led to peptidomimetic compounds which abandon as much as possible the peptidic backbone while retaining the essential functionalities for HIV-1 PR active site inhibition (for reviews on peptidomimetic methodologies see [23] [24] [25] [26] The first step towards HIV-1 PR peptidomimetic inhibitor design is to modify the substrate backbone by replacing the hydrolysis unit in the peptide chain with non-cleavable isosteric fragments and to modify peptidic side chains into non-peptide groups.
Modification of Substrate Backbone
The transition-state isosteres most frequently employed for the synthesis of HIV-1 PR inhibitors are listed in table 1. They comprise statine, hydroxyethyl- 
In order to overcome resistance and to enhance the pharmacokinetic profile of KNI-272, JE-2147 3 was designed [35] , which is a potent HIV-1 PR inhibitor. The compound shows good pharmacokinetic properties attributed to the cyclized P 2 moiety, which seems to confer a good balance between hydrophobicity and lipophilicity [36] .
To illustrate these concepts, we have selected some representative compounds of each bioisosteric class that were designed using the substrate-based approach.
Hydroxyethylamine
Statine
The first HIV-1 PR inhibitor to reach the market was saquinavir 4 . It is characteristic of peptide-based HIV-1 PR inhibitors in which a transition-state analog mimics the tetrahedral intermediate formed during cleavage of the scissile Phe*Pro amide bond of the natural substrate. A vast number of compounds were synthesized in which steric and electronic properties of each side chain and terminal substituent were Pepstatin A and acetyl-pepstatin 1 are general inhibitors of the family of aspartic proteases [28] , and in particular of HIV-1 PR. The absence of the P' 1 side chain reduces hydrophobic contacts with the viral PR active site and leads to relatively low potency (µM) for most statine-containing inhibitors [29] .
To increase potency, norstatine bioisosteres were considered. The norstatine unit is one methylene group shorter than statine and allows the reintroduction of the normal P' 1 residue. KNI-272 2 , a conformationally constrained compound was shown to be a selective and super potent inhibitor of HIV-1 PR, with low toxicity. The high degree of potency of this compound was attributed to conformational preorganization as the overall conformation of KNI-272 in the HIV-1 PR complex is remarkably similar to that observed in single crystal structures of KNI-272 in the free form [30, 31] . However, the pharmacokinetics of KNI-272 are characterized by limited bioavailability, limited distribution and rapid elimination [32] [33] [34] . Moreover, HIV-1 develops in vitro a high level of resistance to KNI-272.
individually modified. Incorporating combinations of preferred side chains into individual molecules resulted in the generation of Ro31-8959 4 [27] .
Nelfinavir 5 results from the optimization of saquinavir and LY289612 9 , which both suffer from poor oral bioavailability, presumably due in part to their retained peptide character [37] [38] [39] . The first cycle of improvement was the discovery of a novel S-phenyl cysteine P 1 -P 3 spanning group. The sulfur proved important for good hydrophobic interaction with the enzyme wall. The P 2 group was then optimized with the elongated P 1 -P 3 group. The best combination of activity and pharmacology was observed for the mesylate salt AG1343 5 [40] . Following publication of a series of potent hydroxyethylamine HIV-1 PR inhibitors, exemplified by saquinavir 4 , it was hypothesized that incorporation of a basic amine into the backbone of the hydroxyethylene L-685,434 series (10) might improve the bioavailability and aqueous solubility of this series of compounds [41, 42] . Indinavir 6 results from the optimization of a series of hydroxyaminopentane amide compounds, that incorporate a basic amine into the hydroxyethylene inhibitor backbone [43] [44] [45] . L735,524 6 is a potent inhibitor and exhibits good oral bioavailability and pharmacokinetic profiles.
extending out to molecular weights of over 1000. In the case of VX-478 7 [46] , the aim was to reduce the molecular weight and increase solubility of the compound while maintaining potency, by using information from the crystal structure to minimize the strain energy in the binding conformation [47] [48] [49] .
Reduced Amide
The first crystallographic structure of an inhibitor in complex with HIV-1 PR was that of compound MVT-101 8 , based on a reduced amide isostere [50] . The poor oral bioavailability and aqueous solubility of these molecules led to the addition of a basic amine into the hydroxyethylene inhibitor backbone. The resulting compounds, nelfinavir and indinavir, revealed potent inhibitors and exhibited good pharmacokinetic profiles.
ability to select rapidly for drug resistant viruses [59, 60] .
Modification of Peptidic Side Chains into Non-peptide Groups
Non-peptide groups will further be preferred over peptidic side chains. A non natural D amino acid can replace a natural L amino acid [61] . For example, in order to keep the affinity of compound LY289612 9 (IC 50 =1.5 nM) towards HIV-1 PR while enhancing its
Difluoroketones
Several nanomolar inhibitors containing difluoroketone [53] [54] [55] Boc=butoxycarbonyl pharmacokinetic profile, a distant analogue of Dcysteine 12 was inserted that was meant to interact with the S 2 subsite of the enzyme active site [52, 62] .
imagined and synthesized (as in 15 [68] [69] [70] ) with various bioisosteres [71, 72] and in pepsin inhibition [73] ).
To obtain pharmacologically useful analogs, the conformation of the peptide can be stabilized into the The observation that peptides interact exclusively in an extended conformation with HIV-1 PR active site has biologically active conformation by the introduction of bridges between different parts of the molecule. The link can involve a single unit (as in compounds 13 [63] and 14 [64] [65] [66] [67] ) or connect two side chains. A motif shown to stabilize enzyme-bound, extended β-structures is cyclisation between P 1 and P 3 side chains. Several original molecules linking subsites P 1 and P 3 (or P' 1 and P' 3 ) in a macrocyclic structure have been led to the concept of a new type of peptidomimetic system in which a greatly modified backbone is integrated into cyclic structures to produce oligopyrrolinones 16 [74] .
These compounds are more resistant towards metabolism than their peptidic analogues and benefit from a high transport into infected cells [75] [76] [77] . An extension of the substrate-based approach utilized an unusual feature of HIV-1 protease. The homodimeric nature of the enzyme led to the suggestion that symmetrical inhibitors might be effective [78] . One of the postulated advantages of this approach was selectivity, as the symmetry demonstrated by the viral enzyme was unique. The resulting inhibitors did indeed demonstrate high levels of selectivity. Beginning with the symmetric inhibitor A77003 17 (K i =84 pM), which displayed low oral bioavailability but adequate anti-HIV activity and aqueous solubility, systematic investigation of peripheral (P 3 and P' 2 ) heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties. Replacement of pyridyl groups with thiazoles, a less electron-rich bioisostere, provided increased chemical stability towards oxidation while maintaining sufficient aqueous solubility for oral absorption and led to Ritonavir 18 [79, 80] .
Screening Approach
The second general strategy for obtaining lead compounds is by screening libraries of compounds for biological activity against HIV-1 PR. The aim is to discover inhibitors of reduced peptidic nature which generally exhibit improved pharmaco-dynamic and kinetic properties than peptide-based compounds typical of the substrate-based approach. The most striking example is probably the discovery of phenprocoumon 19 as a lead non-peptide inhibitor of HIV-1 PR, which was identified via broad screening of the Pharmacia & Upjohn compound library [81] . The goal was to design more potent compounds through SAR studies, and retain the desirable pharmacokinetic characteristics of the 4-hydroxycoumarin class of compounds.
Crystallographic studies provided information on the binding mode of these novel non substrate-based inhibitors, and revealed that the 4-hydroxycoumarin derivatives interact directly with the Fig. (4 ) ]. Iterative cycles of structure-based design led to Tipranavir 20 (PNU-140690, clinical trials), a potent and orally bioavailable nonpeptidic protease inhibitor [82] [83] [84] [85] [86] [87] [88] . (further reading: Parke-Davis [89] [90] [91] [92] [93] [94] [95] [96] [97] ).
An analysis of nonpeptide compounds with useful pharmacological properties led to the identification of natural porphyrins as HIV-1 PR inhibitors (as compound 22). However, the potential usefulness in clinical therapy of these compounds is questioned as the presence of albumin prevents inhibition of HIV-1 PR by this class of compounds [103] .
Screening of traditional medicines and diverse plant extracts, a largely untapped source for structurally novel chemicals, has led to the identification of compounds with anti HIV-1 PR activity (as compound 23) [104] [105] [106] [107] [108] [109] [110] [111] [112] .
Screening programs have highlighted how poorly selective the HIV-1 PR active site is (or how little we understand of structural similarity!) since it can accommodate structurally very diverse molecules. Here are some examples of original attempts to find nonpeptide HIV-1 PR inhibitors. Novel series of penicillinderived C 2 -symmetric inhibitors of HIV-1 PR were identified (as exemplified by compound 21) [98] [99] [100] [101] [102] . Although the compounds were selective and exhibited no cytotoxicity, they suffered from rapid elimination. The disappointing pharmacokinetics prevented the development of these compounds as potential antivirals in the treatment of HIV infections.
Biostructural
Approach or "Rational Drug Design"
The third strategy for generating lead compound is the biostructural approach. Antiviral research has benefited enormously from advances in molecular biology and protein chemistry, which have provided pure proteins in sufficient quantities to allow structural studies to be carried out. These developments, coupled with advances in X-ray crystallography, NMR spectroscopy, and computing technology, have greatly accelerated the determination of 3D structures of proteins. Visualization of these structures by sophisticated computer graphics has made rational drug design feasible. Structural data of the enzyme binding site is now frequently used during the optimization process of compounds that originate from substrate-based design or screening methodologies. An important key design element in many approaches has been to use the C 2 symmetrical nature of the enzyme and the presence of the structural water molecule in the active site to build in specificity and potency (Fig. (4A) ). The design strategy that led to nonpeptide cyclic ureas as potent HIV-1 PR inhibitors was to incorporate the structural water into the inhibitor framework (Fig. (4B) ).
The favorable pharmacokinetics of cyclic ureas led to the identification of the first cyclic urea candidate shortly after its initial design and synthesis [113] . Unfortunately, poor solubility, first-pass metabolism and limited formulation possibilities resulted in poor performances in Phase I studies. Improvement of physical properties and pharmacokinetics without loss of potency led to the design and synthesis of weakly basic cyclic urea analog DMP450 24, currently in clinical trials ( [114, 115] and references therein; recent publications [116] [117] [118] [119] [120] [121] [122] ).
Haloperidol is one of the first non-peptide inhibitor of HIV-1 PR, discovered through a computational screen of 10,000 molecules in the Cambridge Structural Database (CSD) based on steric complementarity with HIV-1 PR active site conformation [123] . Haloperidol is toxic at elevated concentrations and therefore is not itself a viable drug for the treatment of AIDS. Replacement of the ketone functional center with a thioketal ring resulted in ucsf8 25 [124] . In contrast to peptidomimetic inhibitors, ucsf8 interacts mainly with the flaps of the enzyme in an open conformation. The interaction of ucsf8 with the catalytic site of the protease is mediated by a water molecule located at equal distance (3Å) from the two catalytic aspartates Asp25/25'. This water molecule is probably in a similar position to the catalytic water molecule that initiates the hydrolysis of the substrate during the proteolytic process. In the presence of peptidomimetic inhibitors, this water molecule is replaced by hydroxyl groups belonging to the inhibitors and is therefore not observed in the crystallographic structures. Based on this observation, a pharmacophore was designed which takes into account this crucial catalytic water molecule (Fig. (4C) ). The model, which adresses metal-organic compounds particularly, was used for screening new HIV-PR inhibitors through the CSD. Among the structures fitting into the active site of the enzyme, compound Diaqua [bis (2-pyridylcarbonyl) amido] copper (II) Nitrate 26 (SETCEZ) [125] was found to behave as a competitive inhibitor of HIV-1 protease with a K i value of 480 µM [126] .
antifungal antibiotic cerulenin [130] . The carboxylic groups Asp 25 and Asp 25' in the active site are a good target for irreversible inhibition of HIV-1 PR since their inactivation leads to complete loss of the catalytic activity. To date, a few epoxide-based inhibitors of HIV-1 PR have been reported that inactivate HIV-1 PR with high selectivity (UCSF 84, 29) [131] . Haloperidol derivatives with an ynone or an α,β-unsaturated ketone as alkylating functionality were studied but it was discovered that these compounds also led to enzyme inactivation via a sulfhydryl alkylation of the Cys95 belonging to the dimer interface [131] [132] [133] [134] . The tripeptidomimetic epoxide 30, spanning the S3-S1' substrate-binding pockets, was reported as timedependent, irreversible inhibitor of HIV-1 protease (K inact =20 µM) [135] . An increase in the potency of these inhibitors was obtained by extending the peptide sequence [136] [137] [138] . NMR and topochemical studies of irreversible inhibitors containing a cis-epoxide as amide isostere revealed that these compounds prefer to adopt extended conformations similar to the β-strand in solution [139] . Novel irreversible inhibitors containing sulfonamide and sulfone as amide bond isosteres were designed and displayed rapid, timedependent inactivation of HIV-1 protease in the nanomolar range, with high potency in cell culture [140] . New copper coordination compounds, having an octahedral geometry favorable for the orientation of their interacting substituents within the protease subsites were designed and inhibited HIV-1 protease in the micromolar range (as exemplified by complex 27) [127] .
The chemical reactivity of epoxides diminish the potential in vivo efficacy of these compounds as HIV-1 PR inhibitors. It came to conclusion that useful inactivating agents for HIV-1 PR should incorporate a functionality with the reactivity of a cyclic cis-1,2-disubstituted epoxide, preferably one which, like the epoxide, is activated towards nucleophilic addition by specific hydrogen bonding with one of the catalytic aspartate groups. Using haloperidol as a lead structure, compound 31 was designed. The non-peptidic epoxide is an irreversible, active-site directed inhibitor of HIV-1 protease (K inact =65 µM) [133] .
Irreversible Inhibitors
A strategy to suppress the development of resistant strains is to design irreversible inhibitors, as early suggested by the fact that HIV-1 PR is inactivated by 1,2-epoxy-3-(p-nitrophenoxy)propane 28 (EPNP, K inact =9.9 mM) [128, 129] and by the epoxide
Dimerization Inhibitors developed which was > 10000-fold more potent than the starting peptide [144] . The homodimeric nature of the enzyme led to the suggestion that a novel approach to inhibitor design could be considered. This approach, based on the dissociation of enzyme subunits, would ultimately destroy the active site and result in loss of biological activity. In fact, the strategy of using interface peptides to inhibit enzyme activity by interfering with the subunit interaction has been used successfully in the case of ribonucleotide reductase from herpes simplex virus (HSV) [141, 142] and of HIV-1 reverse transcriptase [143] . In the first case, a peptidomimetic drug was HIV protease dimers have significant subunitsubunit interactions in four regions: the 'firemen's grip' at the active site; the flap region with interactions between residues Gly49(49'), Ile50(50'), Gly51(51'); the salt bridges involving Arg8, Asp29 and Arg87, and, the termini of the two subunits, which form a fourstranded antiparallel β-sheet (Fig. (5 ) 69' Fig. (5) . Ionic interactions and hydrogen bonds in the four-stranded β-sheet formed by amino and carboxyl termini. In addition to the hydrogen bonds between main chain C=O and NH groups, there is a salt bridge between the amino terminus of one subunit and the carboxyl terminus of the other subunit. The carboxyl terminus can also form an intersubunit hydrogen bond interaction with His69. There is a network of hydrogen bond linking the side chains of Asn98 and Gly2 from both subunits. residues 25-27; eight occur between residues 6-8, 29, and 87; and 19 hydrogen bonds and two ion pairs are formed by terminal residues 1-4 and 96-99. In fact residues 96-99 contribute 50% of the ionic and 56% of the hydrogen bond intersubunit interactions (which represents 75% of the total Gibbs energy [145] ). This suggests that using peptides as competitive inhibitors of β-sheet formation by the amino and carboxyl termini may efficiently inhibit dimer formation and thus reduce PR activity [146] . K i,dim values. Although consistent with K d estimates by Kettner et al [149] this procedure is still a controversial issue [150] .
Peptidic Inhibitors
To target the dimerization interface by peptidic inhibitors, several approaches can be used. On one hand, a single strand peptide based on the C-terminus or the N-terminus sequences could interfere with one monomer and induce a competition with the homodimer formation (Fig. (6A) ). On the other hand, a double strand peptide could be designed to interdigitate with the HIV protease monomer and reproduce the typical ß-sheet structure (Fig. (6B) ).
There are several reasons for focusing on the dimer interface as a site for antiproteolytic intervention. First, dimerization of the protease polypeptides is essential for activity and represents one of the initial posttranslational steps. Dimerization inhibitors may be able to bind the PR domain in uncleaved gag/pol polyprotein prior to particle assembly. Second, as more than 50% of the intersubunit interactions are provided by the extended interface created by the C-and Ntermini, this interface may be less vulnerable to
C-Terminus and N-Terminus Peptides and Peptidomimetic Inhibitors
Two octapeptides (32 and 33) derived from the sequence of the N-and C-termini of HIV-1 protease were tested for their ability to inhibit HIV-1
Fig. (6).
Approches to inhibit the protease dimerization using peptide inhibitors. Interaction of the PR monomers with A. single sequence peptide B. double sequence peptide mimicking the ß-sheet structure.
mutational escape than the active site or the substrate binding regions of the protease and therefore maintained in a greater number of evolving viral strains. In fact, comparison of the 3D structure and amino acid residues involved in the intermolecular interface of HIV-1 PR in numerous resistant strains are conserved and the fold is nearly superimposable. Therefore, targeting the interface may result in the design of broader acting inhibitors capable of blocking dimerization of HIV protease [147] . Zhang et al have analyzed the kinetics of dimerization inhibition for HIV-1 protease, based on the assumption that the equilibrium between monomers and dimers is rapid (K d = 3.6 ± 1.9 nM at pH=5.0, 0.1 M sodium acetate, 1 M NaCl, 1 mM EDTA buffer, 37 °C) [148] . Their method leads to a distinction between competitive (active-site) inhibitors and dimerization inhibitors as well as the determination of reproduction, but weak inhibitory activity was found with each of the two peptides [151] . Interestingly, the toxicity of such peptides was very low (CC 50 > 197 and 181 µM).
Several other structures derived from the terminal segments showed comparable inhibition [152, 153] . Systematic study of the length requirements for the Nand C-terminal peptide needed for optimum HIV-1 protease inhibition were conducted [154] . The best inhibitory activity was obtained with sequences corresponding exactly to the full length β-strands in the four-stranded β-sheet region of the protease, lending support to the hypothesis that these peptides may interfere with the dimerization interface. It was further observed that inhibitors derived from the C-terminus usually have better inhibitory properties than those 59 from the N-terminus. This can be explained by the stronger binding of this part of the β-sheet to the rest of the molecule (in terms of hydrogen bonds) [152] .
be viewed as a pharmacophore for ulterior peptidomimetic or non-peptidic inhibitor design [157] ( Table 3) .
In order to improve their inhibitory potency, those peptides were systematically modified on the basis of published PR structures, mutation studies and sequence analysis of retroviral proteases, and were modeled into their binding sites. The best-fitting peptides were synthesized and tested in the PR enzyme assay [155, 156] . Several new peptides with improved inhibitory potency were found (see examples in Table 2 ) Among them, the short peptide Ac-T-V-S-F-N-F (IC 50 = 80 µM) mimics the C-terminal part of the gagpol frame shift protein p6*. This suggests a regulatory function of p6* as a dimerization inhibitor of HIV protease in the virion [155] .
Double Sequence Peptide
Since short peptides derived from both PR termini were found active and were designed to target distinct binding sites, attempts were made to combine both inhibitory motifs. Peptides were constructed by connecting the N-and C-terminal sequences with linkers consisting of natural and unnatural amino acids [153, 158] . Tested for inhibitory activity, some of the bifunctional peptides showed an IC 50 lower than one micromolar [158] . The fact that the inhibition constant could be improved so much (about 1000-fold) on the basis of simple rational design supports the hypothesis that these peptides act as dimerization inhibitors. Based on these results, a consensus sequence of potent peptidic inhibitors was established for positions 94-99 of the protease [156] . This consensus sequence can 44 H-LEITLEN-XXX-ISYEL-OH IC 50 = 0.5 µM X = 6-aminohexanoic acid However, these peptides possibly might not interdigitate a single monomer using both halves as in Fig. (6B) , but would rather act as monofunctional peptides as no activity improvement was observed compared to the single peptides. It was proposed that these compounds would dissociate a protease dimer by binding half of the agent into each protease monomer, inherent to the explicit linking of the N-and C-termini of the monomer terminal sequences (see Fig(5 ) ).
peptidic strands. Inhibitions (submicromolecular range) were obtained with molecular tongs containing tripeptidic or tetrapetidic arms linked to pyridinediol-or naphthalenediol-based scaffold (Fig. (8 ) ).
Kinetic studies are in agreement with an interface inhibition mechanism. The more potent inhibitor described by Zutshi et The strategy used to reproduce the ß-sheet structure capable of forming 1:1 complexes with the protease monomer was to covalently crosslink the Ntermini of the protease peptides instead of the N-and C-termini as described in the previous paragraph. Such peptides were shown to inhibit the protease activity and decrease the amount of protease dimer in solution [159] . In HIV-1 PR, the N-terminal ends of residues Pro1 and Cys95 are held at a distance of approximately 10 Å. Different agents were designed to bridge these 10 Å gap while allowing the N-and C-terminal peptides to bind into the appropriate four-stranded β-sheet arrangement with a protease monomer. Agents with tether containing 13-14 methylene groups produced IC 50 values in the low micromolar range (Fig. (7 ) ).
Non Peptidic Inhibitors

Triterpenes-Steroids
The structural consensus features of the docked peptides (Table 3 .) were transformed into pharmacophoric elements and used for the design of non-peptide inhibitors [157, 161] . A virtual screen of the Cambridge Structural Database was conducted using one of the pharmacophore distances (distance range of 1.2 to1.4 nm for OH 97' to COOH 99'). By computer docking, several triterpenes were identified that could fit into the hydrophobic interface site of the relaxed monomer. The IC 50 of these compounds was determined to be in the low micromolar range. The use
The major drawback of the interfacial peptides crosslinked with polyalkyl chains is related to their conformational freedom which induces an unfavorable entropy term in the interaction energy of the inhibitor-HIV-1 PR monomer complex. Bouras et al. [160] designed more rigid "molecular tongs" based on a conformationally constrained scaffold attached to two Fig . (8) . Some "molecular tongs" and their inhibitory activities [160] . of triterpene compounds as cheap building units in the design of non peptide inhibitors presents several advantages: 1) many steroids are used as drugs and have good bioavailability 2) the rigid polycyclic nucleus should reduce the tendency for hydrophobic collapse and loss of entropy generally associated with peptideprotein interactions 3) triterpenes offer multiple possibilities for side chain modifications.
of HIV infection. In summary, the use of defective PR monomers as trans-dominant PR inhibitors offers an elegant way for a single or multifaceted gene therapy approach in the clinical treatment of HIV-1 infection [164] .
Metal-based Inhibitors
Another approach to the inhibition of the protease was suggested from studies on the metal binding to proteins. In fact, such binding could lead to the enzyme inactivation via a metal catalyzed oxidation [165] , or by interfering with the correct binding of the substrate. In order to determine if the protease possesses a sequence susceptible to bind a metal ion, the influence on the protease activity of several metal cations have been studied. Several cations with hard acidic nature such as UO 2 2+ , Ti 4+ , V 5+ , Au 3+ and Pb 2+ [166] or Zn 2+ [167] were found to inhibit the protease activity with IC 50 in the micromolar range. The inhibitory effect was attributed to the binding at, or near the catalytic aspartic residues at the active site level. Unlike those metal species, cupric and mercuric ions tend to bind the sulfhydryl group of cysteine residues and were found to inhibit the protease with activities in the micromolar range [168] . Beside Cys95 which belongs to the dimer interface, the HIV-1 protease possesses another cysteine, Cys67, which lies on the surface of the enzyme and is structurally susceptible to bind a metal cation [16] .
Haloperidol Based Irreversible Inhibitors
The search for active site irreversible inhibitors of HIV-1 protease has led to the discovery that some haloperidol derivatives were also able to inactivate the enzyme via a sulfhydryl alkylation of the Cys95 belonging to the dimer interface [131] [132] [133] . Cys95 derivatization was observed with other sulfhydryl reagents such as DTNB, glutathione [162] Nethylmaleimide and iodoacetamine [128] and could induce an inhibition by interfering with the protease dimerization.
Heterodimer Formation
Another inhibition approach exploiting the dimeric nature of HIV protease is the use of defective monomers or non identical subunits to exchange with wild type homodimers and to produce catalytically defective heterodimers [147, 163] . A structure-based approach was used to identify amino acid substitutions at the dimer interface of HIV-1 PR that would facilitate preferential association of the defective monomers. Expression of those designed PR monomers inhibited activity of the wild-type HIV-1 PR and viral infectivity when assayed in a ex vivo model system. These results show that it is possible to design PR monomers as macromolecular inhibitors that may provide an alternative to small molecule inhibitors for the treatment The essential role of cysteines in the protease inactivation by cupric and mercuric ions has been demonstrated by investigation of a variant protease lacking cysteine residues which were replaced by α-aminobutyric acid [168] . This variant enzyme, which had virtually the same three-dimensional structure and specific activity as the wild-type protein, was not inhibited by copper and mercury. Only in the presence of exogenous chelating agents such as dithiothreitol [168] , ascorbic acid [169] , bathocuproine disulfonic acid [170] or carboxamide ligands [126, 127] was inhibition recovered. In those particular cases, it was again postulated that the synthetic protease was inactivated via a competitive inhibition pattern, by the so-formed metal-organic complexes. Further studies on cupric ion led to the hypothesis that binding to Cys67 could induce allosteric deformation interfering with the correct motion of the flaps. A structural study of HIV-1 PR by NMR has demonstrated that flap motion occurs with compensatory changes in residues 59-75 in a manner of a cantilever [171] . As the flaps close down, the cantilever moves up. The use of two protease mutants, C67S and H69A, supported the implication of Cys67 as a coordinating atom and pointed out the importance of His69 residue as a second ligand for copper [172] . Cys67 and His69 were soon recognized as part of a metal binding sequence Cys67-Gly68-His69-Lys70. In fact, the sequence GlyHis-Lys is a well characterized copper-binding growth factor isolated from human plasma. This tripeptide, which forms a high affinity complex with Cu 2+ , appears to function in the transport of copper, and has diverse biological actions [169] . The reactivity of Cys67 residue would further be enhanced by the presence of His69 and Lys70, which create an electrostatic environment that induces ionization to the thiolate form at acid pH [173] .
These studies cast new light on an interesting site on the protease surface. This site, including residues 59-75, was first described as a cantilever by Harte et al. Among these residues, a short sequence has been pointed out: Cys67-Gly68-His69-Lys70 which can be considered as a metal binding site. Since the binding of copper or the derivatization with DTNB causes inactivation, it seems likely that any molecule which binds to this region has the potential to change the enzyme activity via an oxidation mechanism and/or allosteric deformations. In addition, Cys67 glutathionation experiments have demonstrated one possible mechanism for regulation of the HIV-1 protease through cysteine modification. So, an additional target has been identified that affects protease activity other than the active site or the dimerization site.
Conclusion
Due to its massive threat to health on a global scale, HIV-1 protease has been the subject of extensive studies and to date, the protein is probably one of the most studied enzyme, with more than 80 X-ray and NMR structures available in the PDB. It is estimated that more than 200 structures have been determined since the first crystallographic structure was released in 1989. HIV-1 PR can therefore be considered as an ideal target for drug design methodologies. Most studies have been carried out to design inhibitors targeting the active site of the enzyme. Robust substrate-based methodologies, inspired from renin inhibitor projects and coupled with rational design techniques, have led to several approved drugs: Invirase ® (4 ) (saquinavir mesylate, Hoffmann-LaRoche), Norvir ® (18) (ritonavir, Abott Laboratories), Crixivan ® (6 ) (indinavir sulfate, Merck) and Viracept ® (5 ) (nelfinavir mesylate, Agouron Pharmaceuticals) as well as Amprenavir (VX-478, Glaxo Wellcome, currently in clinical trials). The most striking success using random screening is probably the discovery of phenprocoumon (19) as a lead nonpeptide inhibitor of HIV-1 PR, which was identified via broad screening of the Pharmacia & Upjohn compound library. Iterative cycles of structure-based design led to Tipranavir (20) (PNU-140690, clinical trials), a potent and orally bioavailable nonpeptidic protease inhibitor. Finally, the favorable pharmacokinetics of cyclic ureas led to the identification by rational drug design of the first cyclic urea candidate shortly after its initial design and synthesis. Improvement of physical properties and pharmacokinetics without loss of potency led to the design and synthesis of weakly basic cyclic urea analog DMP450 (24) currently in clinical development. A promising trend in HIV-1 protease inhibition is the development of compounds interfering with the enzyme dimerization process.
Peptides and
On the other hand, the presence of cysteine residues renders the protease especially susceptible to oxidation and disulfide formation. In fact, the addition of copper to the protease at pH 5.5 induce aggregation of the protein, via oxidation of cysteine residues to disulfides [169] . The ready modification of cysteines by copper has led to the investigation of their reactivity with DTNB [5,5'-dithiobis-(2-nitrobenzoic acid) or Ellman's reagent], a sulfhydryl compound which reacts with the ionized form of the cysteine residues [162, 169, 173] . By using three recombinant protease mutants (C67A; C95A; C67A-C95A) it has been demonstrated that each cysteine can be derivatized by DTNB, althought Cys95 derivatization seems to have a greater effect on the loss of activity [162] . The effect of a physiologically relevant sulfhydryl agent, glutathione has also been investigated. It has been shown that if glutathionation of cysteine 95 abolishes activity, the enzyme modified at cysteine 67 with glutathione has increased activity over the unmodified protein. In addition, glutathionation at cysteine 67 markedly stabilized the enzyme activity presumably by reducing autoproteolysis. The greater stability of the glutathiolated enzyme in conjunction with an increase in activity may function to regulate polyprotein processing in vivo [162, 174] . peptidomimetics based on the terminal sequence of the enzyme, a site which is proposed to be less susceptible to mutations, have been shown to lead to HIV-1 PR inactivation. As with therapeutic procedures that successfully combine reverse transcriptase (RT) active site inhibitors and compounds targeting the highly specific RT allosteric TIBO site, it is thought that PR active-site and dimerization inhibitors could provide another option in anti-HIV drug combination strategies. Finally, it is worth noting that an additional target has been identified that affects protease activity, as cupric ion was described to act on a metal-binding sequence on the protease surface, which includes cysteine and histidine residues, leading to the inhibition of the enzyme. 
